Lv1
68 积分 2023-10-08 加入
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
4小时前
已完结
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
22天前
已完结
Bystander effect of antibody–drug conjugates: fact or fiction?
24天前
已完结
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial
1个月前
已关闭
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
2个月前
已完结
Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer
3个月前
已完结
Evolving therapeutic landscape of advanced hepatocellular carcinoma
3个月前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
3个月前
已完结
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
4个月前
已完结
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
4个月前
已完结
皖公网安备34019202002308
